SCHEMBL1490598

SCHEMBL1490598

O=[N+]([O-])c1cnc2cc(Br)ccc2c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.49
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 3/20 0.40
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 2/20 0.40
CTSB P07858 2/20 0.40
GAA P10253 1/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
EGFR P00533 7/20 0.39
TDP1 Q9NUW8 3/20 0.39
HPGD P15428 1/20 0.39
ERN1 O75460 1/20 0.39
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
TNF P01375 1/20 0.38
POLB P06746 1/20 0.38
CRHBP P24387 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30074880 1.00 PTGES (0.49) PTGESALDH1A1MEN1MAPTKMT2A
SCHEMBL358629 0.88 MAPT (0.45) PTGESALDH1A1MEN1MAPTKMT2A
SCHEMBL31424455 0.84 PTGES (0.51) PTGESMEN1MAPTKMT2AEGFR
SCHEMBL30074833 0.82 PTGES (0.49) PTGESMAPTEGFRLMNA
SCHEMBL5767153 0.82 GPR35 (0.46) ALDH1A1MEN1MAPTKMT2AKDM4E
SCHEMBL26620010 0.82 PTGES (0.49) PTGESALDH1A1MAPTCTSBEGFR
SCHEMBL2249257 0.82 TSHR (0.45) ALDH1A1MEN1MAPTKMT2AKDM4E
SCHEMBL202476 0.82 PTGES (0.49) PTGESMAPTEGFRLMNA
SCHEMBL5766464 0.82 TDP1 (0.45) ALDH1A1MEN1MAPTKMT2AKDM4E
SCHEMBL3865236 0.78 CRHBP (0.53) ALDH1A1MEN1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492200-B2 NLRP3 modulators Birstol Myers-Squibb Company (US) 2025-12-09 US disclosed
EP-3921322-B1 PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF CANWELL BIOTECH LTD (HK) 2025-09-03 EP disclosed
US-12351580-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC. (US) 2025-07-08 US disclosed
WO-2025103490-A1 N-OXIDE IMMUNE AGONISTS ACTIVATION BY RADIOTHERAPY Beijing Changping Laboratory (CN) 2025-05-22 WO disclosed
EP-3793613-B1 IMMUNOCONJUGATES BOLT BIOTHERAPEUTICS INC (US) 2025-01-01 EP disclosed
CN-110325534-B Substituted imidazoquinolines as NLRP3 modulators 先天肿瘤免疫公司 2024-04-05 CN disclosed
US-11932663-B2 Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof CANWELL BIOTECH LIMITED (CN) 2024-03-19 US disclosed
US-20240067649-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY INC (US) 2024-02-29 US disclosed
US-20240067649-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY INC (US) 2024-02-29 US disclosed
US-20240067649-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY INC (US) 2024-02-29 US disclosed
EP-1653914-A2 OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS 3M Innovative Properties Company (US) 2006-05-10 EP disclosed
CN-1747953-A Aryl / hetaryl substituted imidazoquinolines. 3M INNOVATIVE PROPERTIES CO (US) 2006-03-15 CN disclosed
WO-2005123080-A2 NITROGEN-CONTAINING HETEROCYCLYL SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-12-29 WO disclosed
EP-1590348-A1 ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2005-11-02 EP disclosed
WO-2005048933-A2 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 WO disclosed
WO-2005048945-A2 HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 WO disclosed
WO-2005018551-A2 OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-03-03 WO disclosed
WO-2005018556-A2 HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-03-03 WO disclosed
US-20040147543-A1 Aryl substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-07-29 US disclosed
WO-2004058759-A1 ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932663-B2 Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof TLR8, TLR7, TLR9 PTGES 1506/4885ALDH1A1 4104/4885MEN1 3328/4885
US-12492200-B2 NLRP3 modulators NLRP3, NLRP1, PYCARD PTGES 419/4885ALDH1A1 864/4885MEN1 3090/4885
US-12351580-B2 NLRP3 modulators NLRP3, NLRP1, NOD1 PTGES 2479/4885ALDH1A1 3584/4885MEN1 3939/4885
US-20240067649-A1 NLRP3 MODULATORS NLRP3, NLRP1, NOD1 PTGES 2479/4885ALDH1A1 3584/4885MEN1 3939/4885
US-20040147543-A1 Aryl substituted imidazoquinolines IL2, IFNG, IRF3 PTGES 296/4885ALDH1A1 730/4885MEN1 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.